CGEM — Cullinan Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $777.76m
- $399.86m
Annual cashflow statement for Cullinan Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -67.5 | 109 | -155 | -168 | -220 |
| Depreciation | |||||
| Non-Cash Items | 27.5 | -247 | 20.9 | 22.4 | 29.7 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.54 | 11.2 | -0.339 | -0.389 | 14.1 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | -43.4 | -127 | -134 | -145 | -176 |
| Capital Expenditures | 0 | -1.13 | -0.208 | 0 | -0.049 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -334 | 250 | 36 | -136 | 180 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -334 | 249 | 35.8 | -136 | 180 |
| Financing Cash Flow Items | -1.76 | -32.1 | 0 | -4.45 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 269 | -25.9 | 40.8 | 266 | 1.09 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -108 | 96.4 | -57.7 | -15.4 | 5.33 |